These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36151805)

  • 1. [Preparation and immungenicity of recombinant protein containing intramolecular adjuvant in SARS-CoV-2 RBD domain].
    Jiang J; Wang Y; Li Y; Wang J; Zhang Y; Wang X; Wang X; Zhang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3353-3362. PubMed ID: 36151805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
    Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
    Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
    Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant.
    Chen Y; Wang Y; Li Z; Jiang H; Pan W; Liu M; Jiang W; Zhang X; Wang F
    Int J Biol Macromol; 2024 Sep; 276(Pt 1):133733. PubMed ID: 39002905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization.
    de Lima VA; Nunes JPS; Rosa DS; Ferreira R; Oliva MLV; Andreata-Santos R; Duarte-Barbosa M; Janini LMR; Maricato JT; Akamatsu MA; Ho PL; Schenkman S
    Immun Inflamm Dis; 2024 Jul; 12(7):e1353. PubMed ID: 39056544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
    Wang Y; Wang L; Cao H; Liu C
    J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
    Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Su QD; Zou YN; Yi Y; Shen LP; Ye XZ; Zhang Y; Wang H; Ke H; Song JD; Hu KP; Cheng BL; Qiu F; Yu PC; Zhou WT; Zhao R; Cao L; Dong GF; Bi SL; Wu GZ; Gao GF; Zheng J
    Vaccine; 2021 Feb; 39(8):1241-1247. PubMed ID: 33516600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
    Bai Y; An C; Zhang X; Li K; Cheng F; Cui B; Song Z; Liu D; Zhang J; He Q; Liu J; Mao Q; Liang Z
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.
    Sun YS; Zhou JJ; Zhu HP; Xu F; Zhao WB; Lu HJ; Wang Z; Chen SQ; Yao PP; Jiang JM; Zhou Z
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.
    Karyagina AS; Gromov AV; Grunina TM; Lyaschuk AM; Poponova MS; Kleymenov DA; Strukova NV; Generalova MS; Ryazanova AV; Galushkina ZM; Dobrynina OY; Bolshakova TN; Sergeeva MV; Romanovskaya-Romanko EA; Krasilnikov IV; Subbotina ME; Lunin VG
    Biochemistry (Mosc); 2022 Apr; 87(4):319-330. PubMed ID: 35527370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of different nanoparticle adjuvants containing recombinant RBD coronavirus antigen in animal model.
    Ataei F; Ahmadi A; Fasihi-R M; Kachoei R; Amani J; Najafi A
    Biotechnol Appl Biochem; 2024 Apr; 71(2):314-325. PubMed ID: 38037222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Phatarphekar A; Vidyadhar Reddy GEC; Gokhale A; Karanam G; Kuchroo P; Shinde K; Masand G; Pagare S; Khadpe N; Pai SS; Vijayan V; Ramnath RL; Pratap Reddy K; Rao P; Harinarayana Rao S; Ramana V
    Vaccine; 2022 Jul; 40(32):4522-4530. PubMed ID: 35718590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein.
    Zhou YF; Nie JJ; Shi C; Ning K; Cao YF; Xie Y; Xiang H; Xie Q
    J Microbiol Biotechnol; 2022 Oct; 32(10):1335-1343. PubMed ID: 36224764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.